BiotechTube

HDM201 + LEE011

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Liposarcoma

Conditions

Liposarcoma

Trial Timeline

Mar 13, 2015 → Oct 16, 2019

NCT ID
NCT02343172

About HDM201 + LEE011

HDM201 + LEE011 is a phase 1 stage product being developed by Novartis for Liposarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02343172. Target conditions include Liposarcoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02343172Phase 1Completed

Competing Products

12 competing products in Liposarcoma

See all competitors
ProductCompanyStageHype Score
Abemaciclib + PlaceboEli LillyPhase 3
77
efatutazoneDaiichi SankyoPhase 2
52
Eribulin MesylateEisaiPhase 1
33
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
52
Yondelis + Yondelis + Dexamethasone + DexamethasoneJohnson & JohnsonPhase 2
52
pazopanibNovartisPhase 2
52
PF-07220060 + MidazolamPfizerPhase 2
51
Sunitinib Malate (SU011248)PfizerPhase 2
51
CabazitaxelSanofiPhase 2
51
INCMGA00012 + PalbociclibIncytePhase 2
49
Selinexor + PlaceboKaryopharm TherapeuticsPhase 2/3
57
Selinexor + IxazomibKaryopharm TherapeuticsPhase 1
25

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85